Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients ( > 55 to 70 years of age) with acute myelogenous leukemia

Purpose: Considerable morbidity and mortality and costs occur during induction therapy for acute myeloid leukemia (AML). Colony-stimulating factors (CSFs) can shorten neutropenia, and may lower costs. We performed a cost-minimization analysis of granulocyte macrophage colony stimulating factor (GM-C...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 1999-02, Vol.10 (2), p.177-182
Hauptverfasser:	Bennett, C. L., Stinson, T. J., Tallman, M. S., Stadtmauer, E. A., Marsh, R. W., Friedenberg, W., Lazarus, H. M., Kaminer, L., Golub, R. M., Rowe, J. M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Biological and medical sciences cost-effectiveness costs Immunotherapy leukemia Medical sciences Pharmacology. Drug treatments sargramostim (GM-CSF)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!